Lung cancer Cancer Malignant neoplasm of bronchus and lung
Conditions
Interventions
Single treatment arm will be used. Methodology: 99mTc-3PRGD2 SPECT/CT scans.
This is a diagnostic, single group assignment, open label efficacy study. Three 99mTc-3PRGD2 SPECT/CT scans will be perform
Sponsors
National Natural Science Foundation (China)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age of 30 - 70 years 2. Clinical pathology in patients with lung cancer 3. Patients without radiotherapy 4. Radiation therapy 5. The clinical plan complete regimen in the treatment of patients 6. Can follow up the survival period of patients 7. Can obtain complete evaluation of the efficacy of imaging data before and after treatment 8. Volunteered to participate in and signed informed consent Clinical diagnosis of pulmonary primary tumor, and without chemotherapy, radiotherapy patients, histologic type is not restricted. Clinical chemotherapy scheme is not restricted. Requirements of each patient in chemotherapy before a week, the first course of chemotherapy after the second chemotherapy was started 1 weeks prior to, and during the first chemotherapy 3 months after the start of the three time points respectively imaging ( including CT, MR and / or US control imaging ). If the patients during the treatment period replacement therapy must be recorded in detail. Requirements for follow-up each survival in patients with stage.
Exclusion criteria
Exclusion criteria: 1. Withdrawal of informed consent 2. Loss to follow-up 3. Against research programme
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Changes of 99mTc-3PRGD2 uptake after one cycle of therapy compared to that after three cycles 2. Determine if the early uptake changes of 99mTc-3PRGD2 after one cycle of therapy compared to the baseline can reflect that of three cycles later | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes of 99mTc-3PRGD2 uptake compared to those of CT and/or PET/CT 2. Determine if the 99mTc-3PRGD2 evaluations either post one cycle or post three cycles of treatment is better than or comparable to those of CT according to the RECIST criteria and/or PET/CT evaluations using PERCIST criteria | — |
Countries
China
Outcome results
None listed